A 59-year-old with HFrEF (EF 30%), CKD stage 3, potassium 4.5. He is on ARNI, beta-blocker, SGLT2 inhibitor. Which additional therapy adds mortality b...

Question

A 59-year-old with HFrEF (EF 30%), CKD stage 3, potassium 4.5. He is on ARNI, beta-blocker, SGLT2 inhibitor. Which additional therapy adds mortality benefit?

Accepted Answer

Add mineralocorticoid receptor antagonist unless contraindicated

Answer

Add nondihydropyridine CCB

Answer

Stop ARNI and use ACEI

Answer

Use digoxin first-line

Answer

Add hydralazine alone

us-abim MCQ (SBA): Heart Failure (MRA)

A 59-year-old with HFrEF (EF 30%), CKD stage 3, potassium 4.5. He is on ARNI, beta-blocker, SGLT2 inhibitor. Which additional therapy adds mortality benefit?